CeriBell (NASDAQ:CBLL) Shares Gap Down on Insider Selling

CeriBell, Inc. (NASDAQ:CBLL) gapped down prior to trading on Wednesday following insider selling activity. The stock had previously closed at $19.90, but opened at $18.82. CeriBell shares last traded at $18.9310, with a volume of 119,076 shares changing hands.

Specifically, CEO Xingjuan Chao sold 2,084 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $19.79, for a total value of $41,242.36. Following the sale, the chief executive officer owned 725,164 shares in the company, valued at approximately $14,350,995.56. This trade represents a 0.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Josef Parvizi sold 16,714 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $20.27, for a total value of $338,792.78. Following the completion of the transaction, the director directly owned 722,652 shares of the company’s stock, valued at $14,648,156.04. This trade represents a 2.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. BTIG Research reiterated a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. JPMorgan Chase & Co. reduced their price objective on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Canaccord Genuity Group boosted their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, CeriBell presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Stock Down 3.7%

The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.25 and a current ratio of 9.73. The stock’s fifty day simple moving average is $21.17 and its two-hundred day simple moving average is $16.21. The company has a market capitalization of $692.58 million, a price-to-earnings ratio of -12.70 and a beta of 1.03.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. On average, sell-side analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Investors Weigh In On CeriBell

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after purchasing an additional 147,013 shares during the period. Yu Fan increased its stake in CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after purchasing an additional 130,964 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after buying an additional 1,162,200 shares in the last quarter. KCM Capital Inc acquired a new position in shares of CeriBell in the fourth quarter worth about $21,930,000. Finally, Novo Holdings A S increased its position in shares of CeriBell by 2.3% in the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after acquiring an additional 20,000 shares in the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.